Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Inhibitors of Viral Protein Synthesis01:30

Inhibitors of Viral Protein Synthesis

Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...
Multiple Sclerosis l: Introduction01:19

Multiple Sclerosis l: Introduction

Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...
Inhibitors Of Virion Release01:25

Inhibitors Of Virion Release

Viral replication and dissemination rely on efficient mechanisms for host cell entry, genome replication, assembly, and release. Influenza viruses, such as types A and B, are negative-sense single-stranded RNA viruses with a segmented genome, that depend on two critical surface glycoproteins to carry out these processes: hemagglutinin (HA) and neuraminidase (NA). HA initiates infection by binding to sialic acid residues on the surface of host epithelial cells, facilitating receptor-mediated...
Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Global overview of multiple sclerosis care units: an international cross-sectional survey.

Frontiers in neurology·2026
Same author

Building sustainable multiple sclerosis registries in Latin America: A practical framework for real-world evidence generation and healthcare access.

Multiple sclerosis and related disorders·2026
Same author

PRO EDI-A Tool to Help Systematic Reviewers Make Equity, Diversity, and Inclusion Assessments.

Cochrane evidence synthesis and methods·2026
Same author

Collaborative Latin American Imaging Network In Neuroimmunology Research (BRAIMS): Rationale, Structure, Challenges, and Future Directions.

Multiple sclerosis and related disorders·2026
Same author

Maternal and Pediatric Use of Vaccines for Mpox: A Living Systematic Review and Meta-analysis of Safety and Effectiveness.

Drug safety·2026
Same author

Endometrial receptivity-guided embryo transfer: a systematic review and meta-analysis of the evidence.

Journal of assisted reproduction and genetics·2026
Same journal

Interventions to prevent or cease electronic cigarette use in children and adolescents.

The Cochrane database of systematic reviews·2026
Same journal

Drugs to improve anaemia, quality of life, and physical function in people with myelodysplastic syndromes (MDS).

The Cochrane database of systematic reviews·2026
Same journal

Interventions for smoking cessation in inpatient psychiatry settings.

The Cochrane database of systematic reviews·2026
Same journal

Mechanical thromboprophylaxis for preventing intradialytic hypotension in people undergoing maintenance haemodialysis.

The Cochrane database of systematic reviews·2026
Same journal

Prognostic models for predicting intensive care unit admission or mortality in critically ill adults not yet been admitted to the intensive care unit.

The Cochrane database of systematic reviews·2026
Same journal

Views and experiences of weight management for people living with mobility‑limiting conditions, intellectual disabilities or severe mental illness: a qualitative evidence synthesis.

The Cochrane database of systematic reviews·2026
See all related articles

Related Experiment Video

Updated: Jun 16, 2026

High-throughput Quantitative Real-time RT-PCR Assay for Determining Expression Profiles of Types I and III Interferon Subtypes
10:00

High-throughput Quantitative Real-time RT-PCR Assay for Determining Expression Profiles of Types I and III Interferon Subtypes

Published on: March 24, 2015

Interferon Beta for primary progressive multiple sclerosis.

Juan Ignacio Rojas1, Marina Romano, Agustín Ciapponi

  • 1Neurology Department, Hospital Italiano Buenos Aires, Gascon 450, Buenos Aires, Buenos Aires, Argentina, 1411.

The Cochrane Database of Systematic Reviews
|January 22, 2010
PubMed
Summary
This summary is machine-generated.

This review found limited evidence on interferon beta for primary progressive multiple sclerosis (PPMS). While not reducing disability progression, it may decrease active brain lesions on MRI, though more research is needed.

More Related Videos

Development and Validation of an Ultrasensitive Single Molecule Array Digital Enzyme-linked Immunosorbent Assay for Human Interferon-α
08:26

Development and Validation of an Ultrasensitive Single Molecule Array Digital Enzyme-linked Immunosorbent Assay for Human Interferon-α

Published on: June 14, 2018

Related Experiment Videos

Last Updated: Jun 16, 2026

High-throughput Quantitative Real-time RT-PCR Assay for Determining Expression Profiles of Types I and III Interferon Subtypes
10:00

High-throughput Quantitative Real-time RT-PCR Assay for Determining Expression Profiles of Types I and III Interferon Subtypes

Published on: March 24, 2015

Development and Validation of an Ultrasensitive Single Molecule Array Digital Enzyme-linked Immunosorbent Assay for Human Interferon-α
08:26

Development and Validation of an Ultrasensitive Single Molecule Array Digital Enzyme-linked Immunosorbent Assay for Human Interferon-α

Published on: June 14, 2018

Area of Science:

  • Neurology
  • Immunology
  • Clinical Trials

Background:

  • Interferon beta (IFNβ) therapies have shown efficacy in relapsing-remitting multiple sclerosis (RRMS).
  • Evidence for IFNβ effectiveness in primary progressive multiple sclerosis (PPMS) remains insufficient.
  • This is an updated Cochrane review assessing IFNβ in PPMS patients.

Purpose of the Study:

  • To evaluate the efficacy and safety of interferon beta (IFNβ) in patients with primary progressive multiple sclerosis (PPMS).
  • To identify and summarize existing evidence from randomized controlled trials (RCTs) on IFNβ for PPMS.

Main Methods:

  • Searched multiple databases (Cochrane, MEDLINE, EMBASE, LILACS, NICE) up to May 2009.
  • Included randomized, double or single-blind, placebo-controlled trials of recombinant IFNβ in PPMS patients.
  • Two reviewers independently extracted data and assessed trial quality.

Main Results:

  • Two RCTs involving 123 patients were included.
  • IFNβ did not demonstrate a significant difference in disease progression compared to placebo (RR 0.89, 95% CI 0.55 to 1.43).
  • Treatment-related adverse events were more frequent with IFNβ (RR 1.90, 95% CI 1.45-2.48).
  • One trial indicated fewer active brain lesions on MRI with IFNβ (WMD -1.3, 95% CI -2.15 to -0.45).

Conclusions:

  • Limited data suggests IFNβ is not associated with reduced disability progression in PPMS.
  • The small trial populations preclude definitive conclusions on IFNβ efficacy in PPMS.
  • Larger studies are required to clarify the role of IFNβ therapy in PPMS.